Q-omics provides the consensus-scored MTO1 profile across patient tissues and cancer cell-line models. MTO1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTO1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MTO1 protein abundance shows 26,181 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where MTO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTO1 survival associations across molecular data types. MTO1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTO1 RNA expression–survival associations across cancer types. High MTO1 expression shows unfavorable associations in KICH, BLCA and LIHC, but favorable associations in KIRC, SKCM and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTO1 RNA expression.
This table summarizes MTO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTO1 shows lower tumor expression in THCA, KICH and KIRP and higher tumor expression in HNSC, LIHC and COAD. The THCA box plot shows higher MTO1 RNA expression in normal versus tumor tissue (log2 FC = −0.351, t-test p < 0.001).
This table shows molecular features associated with MTO1 in patient tissues and cancer cell lines. In patient samples, MTO1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
